CD
CDIX.US Cardiff Lexington Corp
- Market cap
- USD 78.2K
- P/E
- -
- P/B
- -
- ROE
- -735.9%
- Dividend yield
- 63.95%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CDIX.US undervalued?
Graham numberThe Graham number of Cardiff Lexington Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cardiff Lexington Corp fundamental analysis
No fundamental analysis for Cardiff Lexington Corp yet.
Cardiff Lexington Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cardiff Lexington Corp
Cardiff Lexington Corporation, through its subsidiaries, provides orthopedics, spine care, and pain management services in the United States. The company operates through two segments, Healthcare and Real Estate. The company provides diagnostic and surgical services for injuries and disorders of the skeletal system and associated bones, joints, tendons, muscles, ligaments, and nerves. It also engages in real estate business. The company also offers orthopedic and pain proced…
Full company profileCardiff Lexington Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cardiff Lexington Corp annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.15M | 1.63M | 2.23M | 3.71M | 3.45M | 10.0M | 10.7M | 11.9M | 8.27M | 11.5M | 8.39M |
| Gross Profit | 353K | 194K | 756K | 2.04M | 1.78M | 6.16M | 6.63M | 8.29M | 4.43M | 7.21M | 4.72M |
| Operating Income | -2.16M | -2.99M | -2.02M | -1.27M | -1.80M | 1.63M | 3.91M | 5.20M | -194K | 1.10M | -2.12M |
| EBITDA | -1.99M | -2.74M | -2.59M | -5.05M | -1.37M | 2.64M | 3.41M | 5.23M | -108K | 5.65K | -2.12M |
| Net Income | -2.25M | -3.65M | -6.27M | -7.18M | -2.84M | -410K | -5.43M | 3.03M | -3.30M | -6.54M | -11.7M |
| EPS | -1,327 | -3,651,995 | -313,263 | -0.09 | -123,343 | 0.00 | -2,799 | 454 | -0.87 | -0.77 | -0.74 |
| Balance Sheet | |||||||||||
| Total Assets | 2.47M | 1.31M | 3.33M | 4.92M | 4.93M | 11.2M | 13.3M | 20.7M | 23.9M | 29.1M | 30.6M |
| Total Liabilities | 4.07M | 4.90M | 8.18M | 11.6M | 13.8M | 8.38M | 14.8M | 14.1M | 16.3M | 26.0M | 29.0M |
| Shareholders' Equity | -1.60M | -3.59M | -4.85M | -6.73M | -8.87M | 2.78M | -1.47M | 6.62M | 7.60M | 5.54M | 1.59M |
| Cash & Short-term Investments | 62.9K | 69.0K | 159K | 76.9K | 279K | 596K | 219K | 867K | 1.19M | 319K | 584K |
| Total Debt | 758K | 1.11M | 2.40M | 1.97M | 3.97M | - | 3.90M | 6.51M | 9.72M | 18.9M | 25.3M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -198K | -664K | -1.10M | -768K | -948K | -1.04M | -1.04M | -1.72M | -2.65M | -2.85M | -315K |
| Capital Expenditure | 18.7K | 14.5K | 852K | 3.18K | 3.41K | 3.41K | 3.41K | 0.00 | 3.00 | 0.00 | 5.33 |
| Free Cash Flow | -217K | -678K | -1.95M | -771K | -948K | -1.04M | -1.04M | -1.72M | -2.65M | -2.85M | -315K |
| Ratios | |||||||||||
| ROE | - | - | - | - | - | -14.7% | - | 45.7% | -43.5% | -118.0% | -735.9% |
| ROA | -91.2% | -279.0% | -188.0% | -146.1% | -57.5% | -3.7% | -40.7% | 14.6% | -13.8% | -22.5% | -38.3% |
| Net Profit Margin | -196.0% | -224.6% | -281.3% | -193.7% | -82.2% | -4.1% | -50.8% | 25.5% | -39.9% | -56.7% | -139.5% |
| Debt to Equity | - | - | - | - | - | - | - | 0.98x | 1.28x | 3.41x | 15.93x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cardiff Lexington Corp dividends
- Dividend yield
- 63.95%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 50.0K | 0.01 | - |
| 2024 | USD 100K | 0.03 | - |
| 2023 | - | - | - |
| 2022 | USD 204K | 105 | - |
| 2021 | USD 204K | 0.00 | - |
| 2020 | USD 188K | 8,167 | - |
| 2019 | USD 188K | 0.00 | - |
| 2018 | USD 188K | 9,393 | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:3 on Jan 12, 2026.
Who owns Cardiff Lexington Corp
- Insiders 42.96%
- Institutions 0.00%
- Public & others 57.04%
- Shares outstanding 15.6M
- Free float 9.80M
Cardiff Lexington Corp company profile
- Company name
- Cardiff Lexington Corp
- Ticker
- CDIX.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Capital Markets
- Employees
- 15
- Fiscal year end
- December
- Address
- 710 East Main Street, Lexington, KY, United States, 40502
- Phone
- 800 530 2100
- Website
- cardifflexington.com
About Cardiff Lexington Corp
Cardiff Lexington Corporation, through its subsidiaries, provides orthopedics, spine care, and pain management services in the United States. The company operates through two segments, Healthcare and Real Estate. The company provides diagnostic and surgical services for injuries and disorders of the skeletal system and associated bones, joints, tendons, muscles, ligaments, and nerves. It also engages in real estate business. The company also offers orthopedic and pain procedure services, including hip and knee replacement, shoulder reconstruction, fracture care, and hand surgery, as well as spinal surgery. It serves personal injury attorneys, insurance carriers, physical therapy providers, and chiropractic care providers. The company was formerly known as Cardiff International, Inc. and changed its name to Cardiff Lexington Corporation in January 2018. Cardiff Lexington Corporation is based in Lexington, Kentucky.
Cardiff Lexington Corp management
4- Mr. Alex Hunt CunninghamCEO, President & Chairman of the Board · born 1956
- Mr. Matthew T. Shafer CPA, M.B.A.Senior VP, CFO, Chief Accounting Officer & Treasurer · born 1971
- Dr. Kevin Fitzgerald M.D.Managing Director of Nova Ortho & Spine
- Ms. Shannon VitaleController